Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug–drug interaction with ketoconazole

详细信息    查看全文

• 作者：Tao Liu ; Ge Qian ; WenTing Wang ; YanGuo Zhang
• 关键词：GNF ; 351 ; Ketoconazole ; Drug–drug interaction
• 刊名：European Journal of Drug Metabolism and Pharmacokinetics
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：40
• 期：2
• 页码：235-238
• 全文大小：531 KB
• 参考文献：An G, Liu W, Katz DA, Marek G, Awni W, Dutta S (2013) Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug–drug interaction study. Drug Metab Dispos 41(5):1035-045View Article PubMed
  Barouki R, Coumoul X, Fernandez-Salguero PM (2007) The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581:3608-615View Article PubMed
  Bren U, Oostenbrink C (2012) Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations. J Chem Inf Model 52(6):1573-582View Article PubMed
  Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T et al (2010) Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335(1):32-1View Article PubMed Central PubMed
  Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 42(4):759-73View Article PubMed
  Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ (2012) Metabolic map and bioactivation of the anti-tumor drug noscapine. Br J Pharmacol 167(6):1271-286View Article PubMed Central PubMed
  Fang ZZ, Krausz KW, Nagaoka K, Tanaka N, Gowda K, Amin SG et al (2014) In vivo application of the pure aryl hydrocarbon receptor antagonist GNF-351 is limited to the gastrointestinal track. Br J Pharmacol 171(7):1735-746View Article PubMed Central PubMed
  Guner OF, Bowen JP (2013) Pharmacophore modeling for ADME. Curr Top Med Chem 13(11):1327-342View Article PubMed
  Han B, Mao J, Chien JY, Hall SD (2013) Optimization of drug–drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 41(7):1329-338View Article PubMed
  Jin XL, Tang SH, Fang ZZ, Qu YQ, Liang R, Gao ZM, Tang B, Sun DG, Li M, Yang L, Wang LM (2011) Reversible and time-dependent inhibition of CYP3A4-mediated nifedipine oxidation by noscapine. Lat Am J Pharm 30(9):1854-857
  Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X (2014) Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. doi:10.-124/?dmd.-13.-56119 PubMed Central
  Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR et al (2007) Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 322(1):391-98View Article PubMed
  Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF (2013) Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol 69(10):1777-784View Article PubMed
  Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N (2014) Fluoxetine and norfluoxetine mediated complex drug–drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4. Clin Pharmacol Ther. doi:10.-038/?clpt.-014.-0 PubMed
  Shrestha S, Jha AK, Pathak DT, Kharel CB, Basukala SM (2013) Ketoconazole or clotrimazole solution wash as a prophylaxis in management and prevention of fungal infection: a comparative study. Nepal Med Coll J 15(1):31-3PubMed
  Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206:43-9View Article PubMed Central PubMed
  Yan JH, Meyers D, Lee Z, Danis K, Neelakantham S, Majumdar T, Rebello S, Sunkara G, Chen J (2014) Pharmacokinetic and pharmacodynamic drug–drug interaction assessment between pradigastat and digoxin or warfarin. J Clin Pharmacol. doi:10.-002/?jcph.-85
  
• 作者单位：Tao Liu (1)
  Ge Qian (2)
  WenTing Wang (3)
  YanGuo Zhang (1)
  
  1. Department of Dermatology and Venereology, Tangdu Hospital, The Fourth Military Medical University, No.569 Xinsi Road, Xi’an, 710038, China
  2. Department of Dermatology and Venereology, Zhengzhou Children’s Hospital, No. 255 Gangdu Street, Zhengzhou, 450053, China
  3. Department of Pharmacology, School of Pharmacy, The Fourth Military Medical University, No.17 Changle Road, Xi’an, 710032, China
  
• 刊物主题：Pharmacology/Toxicology; Pharmacy; Human Physiology; Pharmaceutical Sciences/Technology; Medical Biochemistry;
• 出版者：Springer Paris
• ISSN：2107-0180

文摘

GNF-351 is a candidate drug used to treat some diseases through antagonizing aryl hydrocarbon receptor. In the present study, molecular docking method was employed to understand the interaction between ketoconazole and GNF-351. The structure of cytochrome P450 (CYP) 3A4 was obtained from protein data bank, and 2-dimensional structure of GNF-351 with standard bond lengths and angles was drawn using chemdraw software. 30 possible binding orientations was generated and docked into the X-ray crystallographic structure of human CYP3A4. The predicted binding mode of GNF-351 into CYP3A4 appeared to adopt an orientation with interactions between their flat aromatic rings and Phe 302 and Phe 304. The comparison for the binding of GNF-351 and ketoconazole into the activity cavity indicated that they exhibited similar distance towards heme, indicating the potential interaction between GNF-351 and ketoconazole. These data remind us the necessary monitoring when future utilization between GNF-351 and ketoconazole.